NEXT – National Experimental Therapy Partnership is a public-private partnership within clinical research consisting of the regions of Denmark, universities, twelve pharmaceutical companies and one GTS institute.
Additionally, NEXT has several associated partners.
The partnership was established on 1 November 2014 as

an INNO+ partnership, with the Innovation Fund Denmark investing DKK 50 million in the partnership over a five year period and the partners investing DKK 114 million. NEXT will make Denmark the pharmaceutical industry’s first choice for early clinical trials of new drugs for patients and with particular focus on Proof of concept trials.

NEXT works hard to optimize all processes from start-up to close out of clinical trials, and here the optimization of legal and regulatory processes are highly prioritized. A high degree of predictability in clinical trials is also an important element for NEXT. Clinical trials are initiated as planned, and the agreed number of patients is recruited.